Amagma Therapeutics is a startup biotechnology company founded by proven serial entrepreneurs including Prof. Tillman Gerngross and Prof. Leonard Zon. Amagma scientists are working on the discovery and development of antibody therapeutics against inflammatory diseases (with a focus on GI disorders) which have proven intractable by other approaches. Amagma is based in Waltham, Massachusetts, and funded by private investors including Polaris Partners.